OAKDALE, Mar. 11th, 2021 - Salspera, LLC, a clinical-stage biopharmaceutical company dedicated to the development of microbial based immunotherapies for cancer, today announced that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting, to be held in a virtual format from April 10th to 15th and May 17th to 21st, 2021.
Title: Microbial based immunotherapy: Saltikva as a novel therapeutic for solid tumors
Session Title: Immunomodulatory Agents and Interventions
Session Category: Immunology
Abstract Number: 5052, e-poster
Salspera is a private, clinical stage biotech company developing its platform of orally administered microbiome immunotherapies in solid tumors. The deep pipeline consists of orally administered microbiome immunotherapies, genetically engineered to eliminate pathogenicity and express various cytokines and cytotoxic proteins within the tumor microenvironment. The lead asset, Saltikva, is currently in an on-going phase 2 clinical study in Stage 4 metastatic pancreatic cancer patients in Canada. It is also being developed in additional solid tumors with the plan to initiate further phase 2 studies. The platform consists of numerous constructs engineered to deliver among others, PD-L1, CTLA-4, IL-15 intra-tumorally. These are currently undergoing IND enabling studies with plans to move them to the clinic.
For more information, please visit
VP of Business Development
Keywords: Saltikva, cancer, oncology, immune, therapy, immunotherapy, bacterial based cancer therapy, microbial immunotherapy, chemotherapy, pancreatic cancer, tumor microenvironment, immuno oncology, interleukin-2, cytokine, bacteria, Salspera